Frederic Chiambaretta

Frederic Chiambaretta

Auto-generated profile, based on publicly available information

Frederic Chiambaretta

Ophthalmology Department, University Hospital Gabriel Monpied, Clermont-Ferrand, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Journal Français d'Ophtalmologie
Verified
Journal Article
Closed access
SDS. Doan
S. Doan
FCF. Chiambaretta
F. Chiambaretta
CBC. Baudouin
C. Baudouin

15 October 2019 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
DBDominique Brémond-Gignac
Dominique Brémond-Gignac
ADAlejandra Daruich
Alejandra Daruich
MRMatthieu P Robert
Matthieu P Robert
FCFrederic Chiambaretta
Frederic Chiambaretta
Introduction: Corneal ulcers normally resolve spontaneously because of the proliferative ability of the corneal epithelium; however, sometimes, epithelial healing is diminished, even when standard treatments are administered. Hence, the treatment of refractory corneal ulcers is challenging and is the subject of ongoing efforts in preclinical and clinical development. Emerging treatment approaches include thymosine β4, CODA001 and topical insulin. Cenegermin eye drops, containing recombinant human nerve growth factor and ReGenerating Agent, a matrix therapy agent, have recently been commercialized for the treatment of moderate to severe neurotrophic keratitis in adults. Areas covered: We describe emerging therapeutic approaches for the management of refractory corneal ulcers and treatments recently introduced to the market. Pubmed and Clinicaltrial.gov databases were first searched including the terms: “corneal ulcer” or “neurotrophic keratopathy” and “treatment”. Each treatment was searched in the same databases separately. Expert opinion: Affections of the sensory corneal nerves are the main factor contributing to the pathophysiology of neurotrophic keratopathy; this explains the healing difficulties of this form of ulcer. Cenegermin is a promising therapy acting as a neurotrophic agent for corneal healing. ReGenerating Agent has led to rapid pain relief and corneal healing, but randomized clinical trials are still necessary for further assessment.

1 March 2017 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PCPhilip Chennell
Philip Chennell
LDL. Delaborde
L. Delaborde
MWM. Wasiak
M. Wasiak
MJM. Jouannet
M. Jouannet
EFE. Feschet-Chassot
E. Feschet-Chassot
Valérie SautouValérie Sautou
Valérie Sautou

1 May 2019 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
JGJose Guell
Jose Guell
ABAnders Behndig
Anders Behndig
Uwe PleyerUwe Pleyer
Uwe Pleyer
SJStéphane Jaulerry
Stéphane Jaulerry
PRPascal Rozot
Pascal Rozot
MLMarc Labetoulle
Marc Labetoulle
Objective: The objective of this study was to compare systemic exposure to tropicamide/phenylephrine following intracameral or topical administration before cataract surgery. Patients and methods: Mydriatics exposure was calculated in patients randomized to intracameral fixed combination of mydriatics and anesthetic ([ICMA]: tropicamide 0.02%, phenylephrine 0.31%, and lidocaine 1%, N=271) or mydriatic eye drops ([EDs]: tropicamide 0.5% and phenylephrine 10%, N=283). Additional doses were permitted if required. Mydriatic plasma levels were determined by mass spectrometric HPLC in 15 patients per group before and after administration. Results: Most ICMA patients (73.6%) received a single dose (200 µL) representing an exposure to tropicamide of 0.04 mg and phenylephrine of 0.62 mg. None of these patients received additional mydriatics. In the control group (three administrations), the exposure was 0.45 (11.3-fold higher than ICMA) and 10.2 (16.5-fold higher) mg. When additional ED was used in this group (9.2% of patients), it was 37.5-fold higher for tropicamide (10 drops, 1.5 mg) and 54.8-fold higher for phenylephrine (10 drops, 34 mg) than the recommended ICMA dose. Tropicamide plasma levels were not detectable at any time point in ICMA patients while it was detectable in all ED patients at 12 and 30 minutes. Phenylephrine was detectable in 14.3% of ICMA patients compared to all ED patients at least at one time point. More ED patients experienced a meaningful increase in blood pressure and/or heart rate (11.2% vs 6.0% of ICMA patients; P=0.03). Conclusion: Systemic exposure to tropicamide/phenylephrine was lower and cardiovascular (CV) effects were less frequent with ICMA. This could be of particular significance in patients at CV risk.

1 January 2015 in Journal Français d'Ophtalmologie
Verified
Journal Article
Closed access
KZK. Zitte
K. Zitte
NBN. Bonnin
N. Bonnin
JKJ.-L. Kémény
J.-L. Kémény
FBF. Bacin
F. Bacin
AMAurélien Mulliez
Aurélien Mulliez
FCF. Chiambaretta
F. Chiambaretta

1 August 2026 in The Journal of Rheumatology
Verified
Journal Article
Closed access
RTRayan Tamba
Rayan Tamba
NBNabil Benmahmoud
Nabil Benmahmoud
FCFrédéric Chiambaretta
Frédéric Chiambaretta